Back to search
FDAFDA · Food and drugs·Recall number D-0091-2023

Glycopyrrolate Tablets, USP, 1 mg, 50 Tablets (5x10) Unit Dose carton, Rx Only, Manufactured for: AvKARE Pulaski, TN 38478, NDC 50268-363-15

Published January 4, 2023 · Recall initiated: December 22, 2022

Summary

FDA records drug Class II recall D-0091-2023, published January 4, 2023 and initiated December 22, 2022. Recalling firm: AVKARE LLC; Status: Completed; Reported quantity: 1237 cartons; Lot: Lot#: 43313, 43342, Exp 12/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Completed — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed impurities/degradation specifications: Out of specification for unknown impurities.

What to do

Voluntary: Firm initiated · Letter

Get an email if GLYCOPYRROLATE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
GLYCOPYRROLATE
Manufacturer
AVKARE LLC
Distributor
USA Nationwide
Lot
Lot#: 43313, 43342, Exp 12/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Glycopyrrolate Tablets, USP, 1 mg, 50 Tablets (5x10) Unit Dose carton, Rx Only, Manufactured for: AvKARE Pulaski, TN 38478, NDC 50268-363-15 recalled?

Yes. FDA published recall D-0091-2023 on January 4, 2023. Reported hazard: Failed impurities/degradation specifications: Out of specification for unknown impurities.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: GLYCOPYRROLATE.